Release Date: December 22, 2025

Expiration Date: December 22, 2026

Activity Overview

This session of the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) focused on the management of pancreatic adenocarcinoma and GI neuroendocrine tumors. The expert faculty provided updates on special topics in pancreatic cancer, including neoadjuvant therapy for resectable disease and the use of metastasis-directed therapy in oligometastatic pancreatic cancer.

This was followed by lectures on current and emerging systemic therapy landscapes for pancreatic and neuroendocrine tumors. The session concluded with a case presentation and lecture on emerging molecular biomarkers for potentially curable neuroendocrine tumors.

Registration is also now open for ISGIO 2026, taking place October 2-3, 2026, in Ft Lauderdale, Florida. Click here to learn more.

Target Audience

This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Incorporate biomarker testing results to individualize treatment selection for patients with GI cancers
Incorporate novel data to effectively sequence available therapies for optimal outcomes in patients with GI cancers

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.75 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Exact Sciences Corporation; Exelixis, Inc; and Partner Therapeutics, Inc.

PER is proud to partner with the Cholangiocarcinoma Foundation (CCF), GI Cancers Alliance, and Memorial Sloan Kettering Cancer Center.

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

GET STARTED WITH THIS PROGRAM:

Related Content